research Successful treatment of refractory folliculitis decalvans with secukinumab
Secukinumab effectively treated a difficult case of folliculitis decalvans.
Search
for
Sort by
Research
360-390 / 1000+ results
research EVIDÊNCIAS ACERCA DO USO DO ANTICORPO MONOCLONAL TOCILIZUMABE COMO TERAPÊUTICA PARA COVID-19
Tocilizumab might be an effective treatment for COVID-19.
research Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
research [Bimatoprost promotes hair growth of reconstructed hair follicles in mice through activation of the Wnt/β-catenin signaling pathway].
Bimatoprost helps mouse hair grow by turning on a specific growth pathway.
research USE OF IVERMECTINE AS TOPICAL APPLICATION IN TREATMENT OF RABBIT MANGE
Ivermectin 0.1% is the best and safest topical treatment for rabbit mange.
research 438 Laminin-511 is a new player in the development of psoriasis and controlled via cannabinoid receptor type 1
Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.
research Examination of epigenetic inhibitor zebularine in treatment of skin wounds in healthy and diabetic mice
Zebularine improved skin structure but delayed wound healing in diabetic mice.
research Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
research Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.
research Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review
Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
research Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
research Efficacy and safety of systemic monotherapy in the management of generalized pustular psoriasis: A systematic review
Different treatments for skin conditions were found to be effective and generally safe, with biologics recommended as the first choice for generalized pustular psoriasis.
research Mesalazine in the treatment of extensive alopecia areata: A new therapeutic option?
Mesalazine may help treat extensive alopecia areata effectively.
research Imiquimod for Cervical and Vaginal Intraepithelial Neoplasia
Imiquimod may be a better non-surgical treatment for cervical pre-cancer, but its effectiveness for vaginal pre-cancer is unclear, and it has some side effects.
research Complete hair regrowth in a young male with severe atopic dermatitis and alopecia areata after dupilumab: probably more than a coincidence
Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.
research Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
Dupilumab helps children with alopecia areata regrow hair safely.
research The Intervention Effect of Externally Applying or Orally Administering Bifidobacterium animalis Subsp. lactis J12 on Atopic Dermatitis Induced by 2,4-Dinitrofluorobenzene
Bifidobacterium animalis subsp. lactis J12 helps reduce atopic dermatitis symptoms.
research Treatment of Eyebrow Hypotrichosis Using Bimatoprost: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study
Bimatoprost effectively and safely improves eyebrow appearance.
research Onset of frontal fibrosing alopecia during inhibition of Th1/17 Pathways with ustekinumab
Ustekinumab treatment didn't prevent frontal fibrosing alopecia.
research Alopecia areata after dupilumab for atopic dermatitis
Dupilumab for eczema may cause hair loss.
research 415 IL-17C: Checkpoint in innate skin immunology
IL-17C is important in inflammatory skin diseases and could be a target for treatment.
research JAK-inhibitors in dermatology: current evidence and future applications
JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination
IMSG nanoparticles improve vaccine delivery and immune response through hair follicles.
research Bimatoprost for the treatment of female androgenetic alopecia—A case report
research Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
research 061 Selective inhibition of tyrosine kinase 2 prevents and restores interleukin-12-induced hair follicle immune privilege collapse: a novel approach to alopecia areata therapy?
Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
research Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome
Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.